Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

被引：0
|
作者：
Fuchs, Charles S.
Denker, Andrew E.
Tabernero, Josep
Van Cutsem, Eric
Ohtsu, Atsushi
Lam, Baohoang
Koshiji, Minori
Bang, Yung-Jue
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Merck & Co Inc, Kenilworth, NJ USA
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium
[5] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[6] Seoul Natl Univ, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.tps4135
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4135
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
    Li, Hongli
    Deng, Jingyu
    Ge, Shaohua
    Zang, Fenglin
    Zhang, Le
    Ren, Peng
    Wang, Baogui
    Cao, Fuliang
    Deng, Ting
    Liu, Rui
    Ning, Tao
    Yang, Yuchong
    Bai, Ming
    Wang, Xia
    Ji, Zhi
    Duan, Jingjing
    Liu, Yong
    Zhou, Dejun
    Liang, Han
    Ba, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Phase II Study of Pembrolizumab (MK-3475) in Patients with metastatic castration-resistant Prostate Cancer (KEYNOTE-199)-Study AP 93/16 of the AUO
    Rexer, H.
    Graefen, M.
    Merseburger, A.
    UROLOGE, 2017, 56 (11): : 1471 - 1472
  • [23] KEYNOTE-062:Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Kher, Uma
    Lam, Baohoang
    Koshiji, Minori
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
    Tabernero, Josep
    Bang, Yung-Jue
    Van Cutsem, Eric
    Fuchs, Charles S.
    Janjigian, Yelena Yuriy
    Bhagia, Pooja
    Li, Kan
    Adelberg, David
    Qin, Shu Kui
    FUTURE ONCOLOGY, 2021, 17 (22) : 2847 - 2855
  • [25] Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
    Tabernero, Josep
    Van Cutsem, Eric
    Bang, Yung-Jue
    Fuchs, Charles S.
    Wyrwicz, Lucjan
    Lee, Keun Wook
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol
    Salguero, Hugo Raul Castro
    Mansoor, Wasat
    Braghiroli, Maria Ignez Freitas Melro
    Goekkurt, Eray
    Chao, Joseph
    Wainberg, Zev A.
    Kher, Uma
    Shah, Sukrut
    Kang, SoonMo Peter
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
  • [26] Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma: An updated analysis.
    Yushak, Melinda Lynne
    Lawson, David H.
    Goings, Monica
    Mckellar, Marjorie
    Maynard, Necia
    Woodruff, Kristin Sieja
    Gorgoglione, Caroline
    McBrien, Stephanie
    Delman, Keith A.
    Lowe, Michael C.
    Kudchadkar, Ragini Reiney
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475)
    Doi, Toshihiko
    Piha-Paul, Sarina Anne
    Jalal, Shadia Ibrahim
    Mai-Dang, Hieu
    Saraf, Sanatan
    Koshiji, Minori
    Csiki, Ildiko
    Bennouna, Jaafar
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [28] Phase-II-Studie zu Pembrolizumab (MK-3475) bei Patienten mit metastasiertem kastrationsresistenten Prostatakarzinom (KEYNOTE-199) – Studie AP 93/16 der AUOPhase II study of pembrolizumab (MK-3475) in patients with metastatic castration-resistant prostate cancer (KEYNOTE-199)—study AP 93/16 of the AUO
    H. Rexer
    M. Graefen
    A. Merseburger
    Der Urologe, 2017, 56 (11): : 1471 - 1472
  • [29] Phase Ib/II study of combination therapies with pembrolizumab (MK-3475) in patients with mCRPC (KEYNOTE-365) - study AP 94/16 of the AUO
    Rexer, H.
    Retz, M.
    Hammerer, P.
    UROLOGIE, 2023, 62 (12): : 1370 - 1371
  • [30] KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer.
    Cohen, Ezra E. W.
    Machiels, Jean-Pascal H.
    Harrington, Kevin J.
    Burtness, Barbara
    Shin, Sang Won
    Gause, Christine K.
    Swift, Ann M.
    Brown, Holly
    Perrone, Andrea Marie
    Cheng, Jonathan D.
    Swaby, Ramona F.
    Le Tourneau, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345